LivaNova (LIVN) Net Cash Flow Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -562.50% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -564.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 76.43% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -31.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -394.13% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 57.36% |
| 10 | LivaNova | 4.03 Bn | 3.45 Bn | 243.75 Mn | -1,149.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,149.78% |
| Dec 31, 2025 | -116.65% |
| Sep 30, 2025 | 80.28% |
| Jun 30, 2025 | -919.53% |
| Mar 31, 2025 | -78.13% |
| Dec 31, 2024 | 75.41% |
| Sep 30, 2024 | 667.20% |
| Jun 30, 2024 | 65.62% |
| Mar 31, 2024 | 909.53% |
| Dec 31, 2023 | 504.00% |
| Sep 30, 2023 | -96.31% |
| Jun 30, 2023 | 134.92% |
| Mar 31, 2023 | -98.28% |
| Dec 31, 2022 | -77.05% |
| Sep 30, 2022 | 170.42% |
| Jun 30, 2022 | -142.79% |
| Mar 31, 2022 | 18,077.59% |
| Dec 31, 2021 | 13.91% |
| Sep 30, 2021 | -2,429.79% |
| Jun 30, 2021 | -27.88% |
| Mar 31, 2021 | -98.04% |
| Dec 31, 2020 | 254.71% |
| Sep 30, 2020 | -118.06% |
| Jun 30, 2020 | 1,672.76% |
| Mar 31, 2020 | 1,581.87% |
| Dec 31, 2019 | 52.47% |
| Sep 30, 2019 | -2.96% |
| Jun 30, 2019 | 47.41% |
| Mar 31, 2019 | 112.69% |
| Dec 31, 2018 | -213.57% |
| Sep 30, 2018 | 54.18% |
| Jun 30, 2018 | 41.72% |
| Mar 31, 2018 | -237.72% |
| Dec 31, 2017 | 224.64% |
| Sep 30, 2017 | 5,886.22% |
| Mar 31, 2017 | 184.97% |